EUCTR2010-021068-13-DE进行中（未招募）不适用
An open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis adsorbed vaccine (REPEVAX) administered concomitantly versus non-concomitantly with an influenza vaccine (VAXIGRIP) to subjects of 60 years of age and older
Sanofi Pasteur MSD S.N.C.0 个研究点目标入组 954 人开始时间: 2010年6月29日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 954
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects have to meet all the following criteria to be eligible for inclusion:
- •1. Adults aged =60 years at Visit 1
- •2. At least one documented booster dose with a tetanus- and diphtheria-containing vaccine between 5 and 15 years before Visit 1
- •3. No influenza vaccine administered during the last 6 months before Visit 1
- •4. Signed the informed consent form before any specific study procedure
- •5. Subject able to attend all scheduled visits and to comply with all study procedures.
- •6. For France only: Subject affiliated to a health social security system
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects must not be included in the study if they meet at least one of the following criteria:
- •1. Suspected or documented receipt of a booster dose with a tetanus or diphtheria- or poliomyelitis- containing vaccine within the last 5 years before Visit 1
- •2. Suspected or documented receipt of pertussis-containing vaccine within the last 10 years before Visit 1
- •3. Medically diagnosed pertussis disease within the last 10 years before Visit 1
- •4. Receipt of any live virus vaccine within 28 days before Visit 1, or planned vaccination with any live virus vaccine during the study
- •5. Receipt of any other inactivated vaccine within 14 days before Visit 1, or planned vaccination with any other inactivated vaccine during the study
- •6. Febrile illness (body temperature =38.0°C) or moderate or severe acute illness/infection at Visit 1, according to investigator judgment
- •7. History of hypersensitivity or anaphylactic or other allergic reactions to egg proteins, chick proteins, formaldehyde, glutaraldehyde, polymixin B, neomycin, streptomycin and octoxinol 9, or to any of the vaccine components, or history of a life-threatening reaction to the study vaccines or a vaccine containing any of the same substances
- •8. History of Guillain Barré syndrome or brachial neuritis following a previous vaccination
- •9. History of encephalopathy of unknown origin within 7 days after immunization with a pertussis-containing vaccine or unstable neurological disorders
- •10. Known or suspected immune dysfunction that is caused by a medical condition, or any other cause
- •- Examples: immune dysfunction including congenital immunodeficiency, human immunodeficiency virus (HIV) infection, organ or bone marrow transplantation, acute or chronic leukaemia, lymphoma, Hodgkin’s disease, multiple myeloma, other conditions affecting the bone marrow or the lymphatic system or generalized malignancy
- •- Exceptions: subjects with prostate or breast cancer with no chemotherapeutic drugs or receiving only hormone blocking drugs, subjects with skin cancer who are not receiving radiation therapy or chemotherapy, and subjects with a history of other malignancies who have been disease-free for at least 6 months before Visit 1 can be included
- •11. Receipt of immunosuppressive therapy or expected to receive immunosuppressive therapy during the study like:
- •- Chemotherapy agents to treat cancer received within 6 months before Visit 1
- •- Daily -or on alternate days- systemic corticosteroids at a dose =20mg/day of prednisone (or equivalent) for =14 days within 4 weeks before Visit 1
- •- Immunomodulator therapy within 6 weeks before Visit 1
- •12. Thrombocytopenia, bleeding disorder or anticoagulants within 3 weeks before Visit 1 contraindicating intramuscular vaccination
- •13. Receipt of immunoglobulins or any blood products, other than autologous blood transfusion, given within 5 months before Visit 1 or planned treatment with immunoglobulins or blood products during the study
- •14. Chronic disease (e.g., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric) that is unstable or any intercurrent illness that might interfere with the ability to participate fully in the study; or interfere with evaluation of the vaccine
- •15. Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalised without his/her consent
- •16. Participation to another clinical study investigating a vaccine, drug, medical device, or medical procedure within 4 weeks before Visit 1.
研究者
相似试验
进行中（未招募）
1 期
An open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis adsorbed vaccine (REPEVAX) administered concomitantly versus non-concomitantly with an influenza vaccine (VAXIGRIP) to subjects of 60 years of age and olderEUCTR2010-021068-13-FRSanofi Pasteur MSD S.N.C.
进行中（未招募）
1 期
A randomised, multi-centre, open-label study to evaluate the efficacy of VANIQA with laser treatment versus laser treatment alone in female subjects with excessive facial hair (facial hirsutism)Excessive facial hair in females (Facial hirsutism)MedDRA version: 8.1Level: LLTClassification code 10020112Term: HirsutismEUCTR2006-002833-19-ATShire Pharmaceutical Development200
进行中（未招募）
不适用
A randomised, multi-centre, open-label study to evaluate the efficacy of VANIQA with laser treatment versus laser treatment alone in female subjects with excessive facial hair facial hirsutism - NDfacial hirsutismMedDRA version: 6.1Level: SOCClassification code 10040785EUCTR2006-002833-19-ITShire Pharmaceutical Ltd200
进行中（未招募）
不适用
An open-label, randomized, multicenter study to evaluate the use of Zoledronic Acid in the prevention of cancer treatment-related bone loss in postmenopausal women with ER+ and/or PgR+ breast cancer receiving Letrozole as adjuvant therapy - ZoFast2406Prevention of cancer treatment-related bone loss in postmenopausal women with ER+ and/or PgR+ breast cancer receiving Letrozole as adjuvant therapyEUCTR2004-001369-17-ESovartis Farmacéutica S.A.400
进行中（未招募）
不适用
A randomized, open-label, multi-center study to evaluate the efficacy of nilotinib versus best supportive care with or without a tyrosine kinase inhibitor (investigator´s choice) in adult patients with gastrointestinal stromal tumors resistant to both imatinib and sunitinibGastrointestinal stromal tumors (GIST)EUCTR2006-002267-11-DEovartis Pharma Services AG237